

GCOM 2019

3RD GLOBAL CONFERENCE ON MYOSITIS


Conference Programme Overview

Wednesday, 27 March 2019

- 10:00 – 12:30** **Pre-Congress Pathology Workshop:** Make the diagnosis - difficult cases including morphology – *A Amato (USA), A Mammen (USA), I Nishino (Japan)*
- 12:30 – 14:00** Lunch
- 14:00 – 15:00** **Welcome** – *O Benveniste (France), I Nishino (Japan) & W Stenzel (Germany)*
General Lecture: Recent developments in therapeutic approaches for neuromuscular diseases – *T Voit (UK)*
- 15:00 – 16:30** **I Sporadic Inclusion Body Myositis (sIBM)** – *T Lloyd (USA), J Zschüntzsch (Germany)*
- 15:00 – 15:25** **1:** Muscle aging – *M Kjaer (Denmark)*
- 15:25 – 15:50** **2:** Pathogenic mechanisms connecting inherited and acquired inclusion body myopathy – *C Wehl (USA)*
- 15:50 – 16:30** **3:** Selected oral presentations
Xenograft model of sporadic inclusion body myositis – *K Britson (USA)*
Targeting highly differentiated effector memory KLRG1⁺ cytotoxic T cells in inclusion body myositis – *S Greenberg (USA)*
CD8⁺T-bet⁺ cells as a predominant biomarker for inclusion body myositis – *G Dzangué-Tchoupou (France)*
- 16:30 – 17:15** Coffee Break
- 17:15 – 18:30** **Ila Extramuscular (Neoplasia)** – *Y Allenbach (France), M de Visser (The Netherlands)*
- 17:15 – 17:40** **1:** Lessons learnt from immune checkpoint inhibitor cardiovascular toxicities – *J Moslehi (USA)*
- 17:40 – 18:30** **2:** Selected oral presentations
Overall and site-specific cancer risk before and after diagnosis of idiopathic inflammatory myopathies: Novel register data from 2002 to 2016 in Sweden – *L Dani (Sweden)*
Immunization of dermatomyositis-specific auto-antigen transcriptional intermediary factor (TIF1)- γ induces myositis in mice – *N Okiyama (Japan)*
The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody positive dermatomyositis – *A Oldroyd (UK)*
Pruritogenic mediators in skin samples of patients with dermatomyositis – *A Vincze (Hungary)*
- 18:30** **Welcome Reception:** Berlin history in a nutshell – *J Marberg (Germany)*

Thursday, 28 March 2019

- 08:30 – 10:00** **Ilb Extramuscular (Lung)** – *B Hervier (France), M Needham (Australia)*
- 08:30 – 08:55** **1:** How to evaluate clinical outcomes of myositis-associated interstitial lung disease – *M Kuwana (Japan)*
- 08:55 – 09:20** **2:** Lungs as a trigger of autoimmunity: The role of environmental factors – *L Klareskog (Sweden)*
- 09:20 – 10:00** **3:** Selected oral presentations



GCOM 2019

3RD GLOBAL CONFERENCE ON MYOSITIS

High level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis – Q Peng (China)

Anti-MDA5 antibody-associated dermatomyositis: Three subgroups with different outcomes – S Toquet (France)

Risk stratification in patients with anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease treated initially with intensive combination regimen – T Gono (Japan)

10:00 – 11:15 Coffee Break, Exhibition and Poster Session

11:15 – 12:45 III Treatment and Trials – B Feldman (Canada), O Landon-Cardinal (Canada)

11:15 – 11:40 **1:** Bayesian statistics for rare diseases (from registries to clinical trials) – **L Biard (France)**

11:40 – 12:05 **2:** Trial readiness in rare diseases – **V Straub (UK)**

12:05 – 12:45 **3:** Selected oral presentations

Quantitative high throughput screening of small molecule libraries to inhibit interferon beta-stimulated major histocompatibility complex class I in myositis muscle – T Kinder (USA)

Study of Tofacitinib in refractory dermatomyositis – J Paik (USA)

A one-year study investigating the effect of specialised and intensive ADL training in patients with idiopathic inflammatory myopathies - preliminary results – M Špiritović (Czech Republic)

12:45 – 14:00 Lunch

14:00 – 16:00 Workshop for Young Physicians/Researchers: Clinics & Research: Specificities in different countries. How to improve international collaborations? – O Benveniste (France), H Chinoy (UK), L Christopher-Stine (USA), M Fujimoto (Japan), A Mammen (USA), I Nishino (Japan), W Stenzel (Germany)

14:00 – 16:00 Patient-Centered Workshop – J Schmidt (Germany), S Schlüter (Germany)

1: How to assess patient reported outcome (PRO)

PRO in IIM: Where do we stand – **C Mecoli (USA)**

e-technologies in IIM – **O Landon-Cardinal (Canada)**

Devices in IIM – **R Aggarwal (USA)**

2: 1h Q&A with patients

16:00 – 16:45 Snack Break, Exhibition and Poster Session

16:45 – 20:00 Team Workshop jDM – K Adelan (USA), L Rider (USA)

1: Medication usage and outcomes in jDM – **T Kishi (Japan)**

2: Insights from genomic analyses of jDM – **C Deakin (UK)**

3: Biomarkers of disease activity in jDM: Opportunities for personalised treatment strategies – **F v. Wijk (The Netherlands)**


4: Vasculopathy in jDM and work in progress – **C Gitiaux (France)**

5: Selected oral presentations

The use of metabolomics to develop novel biomarkers for juvenile dermatomyositis – J Dvergsten (USA)

Endothelial biomarker profiles reflect heterogeneity of juvenile dermatomyositis and may predict disease course – J Wienke (The Netherlands)

The relationship of pain, fatigue and emotional distress with quality of life in juvenile myositis – K Ardalán (USA)



GCOM 2019

3RD GLOBAL CONFERENCE ON MYOSITIS

Juvenile dermatomyositis – data of a national pediatric rheumatology database –
C Sengler (Germany)

16:45 – 18:45 **Speed Funding** – *Y Allenbach (France), H Chinoy (UK), A Kubota (Japan), A Meyer (France), D Pehl (UK), C Preuß (Germany), J Tanboon (Japan)*

Presentation of the six finalists

Interferon-mediated impairment of myogenic precursor cells in dermatomyositis –
L Gallay (France)

The pathogenesis and treatment of inclusion body myositis in a xenograft model –
K Britson (USA)

Mechanisms underlying the therapeutic and iatrogenic response to glucocorticoids in skeletal muscle during inflammatory myopathies – **M Giannini** (France)

Inclusion body myositis on a chip – **S Lassche** (The Netherlands)

CD27-CXCR4hiCD21lo cells in Jo1-positive IIM – **E Wilfong** (USA)

Heart involvement and autoantibody profile in myositis – **S Korsholm** (Denmark)

Friday, 29 March 2019

08:30 – 10:00 **IVa Juvenile Dermatomyositis (jDM)** – *A Selva O' Callagan (Spain), B Bader-Meunier (France)*

08:30 – 08:55 **1:** Human type I interferonopathies – **Y Crow** (France)

08:55 – 09:20 **2:** The vasculopathy in jDM – **D Eleftheriou** (UK)

09:20 – 10:00 **3:** Selected oral presentations

Mitochondrial dysfunction: A novel treatment focus in juvenile dermatomyositis –
M Wilkinson (UK)

Differential peripheral IFN score expression in juvenile dermatomyositis vs. Mendelian interferonopathies – **H Kim** (USA)

Juvenile inflammatory myopathy with anti-MDA5 auto-antibodies: A specific subgroup demonstrating differentially enhanced upregulation of interferon-alpha signaling – **I Melki** (France)

10:00 – 11:15 Coffee Break, Exhibition and Poster Session

11:15 – 12:30 **IVb Dermatomyositis (DM)** – *M Fujimoto (Japan), V Werth (USA)*

11:15 – 11:40 **1:** Ways to differentiate DM subtypes – **W Stenzel** (Germany)

11:40 – 12:30 **2:** Selected oral presentations

Identification of six dermatomyositis subgroups using principal component analysis-based cluster analysis – **H Zhu** (China)

Overexpression of type 1 IFN in skeletal muscle affects muscle function – **M Morales** (USA)


The role of low-density granulocytes (LDGs) and neutrophil extracellular traps (NETs) in the clinical profile of patients with idiopathic inflammatory myopathies – **J Torres-Ruiz** (Mexico)

Auto-antibodies targeting components of sarcolemma membrane repair: A pathogenic mechanism in inflammatory myopathies – **W Jarjour** (USA)

12:30 – 14:00 Lunch / **Genzyme Industry Symposium**

14:00 – 15:30 **V Immune-Mediated Necrotizing Myopathies (IMNM)** – *I Lundberg (Sweden), G Wang (China)*

14:00 – 14:25 **1:** Macrophages - multidimensional players in inflammatory diseases – **J Schultze** (Germany)



GCOM 2019

3RD GLOBAL CONFERENCE ON MYOSITIS

- 14:25 – 14:50 **2:** Auto-antibodies at the center of IMNM pathogenesis – **O Boyer** (France)
- 14:50 – 15:30 **3:** Selected oral presentations
Investigating chaperone-mediated selective autophagy in immune-mediated necrotizing myopathies – **N Fischer** (Germany)
Severe axial and pelvifemoral muscle damage in immune-mediated necrotizing myopathy evaluated by whole-body MRI – **O Landon-Cardinal** (Canada)
Role of MircoRNAs in immune-mediated necrotizing myopathy through regulation of myogenic differentiation-associated genes – **Y Zuo** (China)
- 15:30 – 16:30 Snack Break, Exhibition and Poster Session
- 16:30 – 17:00 **IMACS Meeting** – *F Miller (USA), L Rider (USA)*
- 17:00 – 17:30 **Establishing a World Myositis Society: Where do we go from here?** – *J Schmidt (Germany)*
- 18:30 **Scientific Get-Together**

Saturday, 30 March 2019

- 08:30 – 09:20 **VI New Treatment Options** – *U Schneider (Germany), S Greenberg (USA)*
- 08:30 – 08:55 **1:** How treatment of haematological malignancies paves the way for future treatment strategies for auto-immune and inflammatory diseases – **O Hermine** (France)
- 08:55 – 09:20 **2:** Next generation weapons for myositis: Biological or not? – **R Aggarwal** (USA)
- 09:20 – 10:00 **VII Miscellaneous** – *O Boyer (France), J Lamb (UK)*
Selected oral presentations
The interferon gene signature in dermatomyositis, the anti-synthetase syndrome, immune-mediated necrotizing myopathy, and inclusion body myositis: A comparative study – **I Pinal-Fernandez** (USA)
Evaluation of a novel particle-based assay for detection of myositis specific antibodies – **K Malyavantham** (USA)
Optimization of muscle NMR imaged segmentation to best discriminate disease progression in adult patients with inflammatory myopathies – **H Reyngoudt** (France)
- 10:00 – 10:30 Coffee Break, Exhibition
- 10:30 – 11:15 **VIII Hot Topics** – *HH Goebel (Germany), J Vencovský (Czech Republic)*
Selected oral presentations
Identification of novel auto-antibodies for idiopathic inflammatory myopathies using human proteome microarray – **L Li** (China)
IFN level assessed by ultrasensitive detection technology in myositis patients: A promising biomarker of disease activity in dermatomyositis and anti-synthetase syndrome – **L Bolko** (France)
Analysis of muscle transcriptomic features in idiopathic inflammatory myopathies – **H Chen** (China)
- 11:15 – 12:00 **IX Patients:** Reports from patient association(s) – *M Dimachkie (USA)*
- 12:00 – 13:00 **General Discussion, Prizes** – *T Lloyd (USA) & V Werth (Australia), Closing & Handover* – *O Benveniste (France), I Nishino (Japan) & W Stenzel (Germany)*
- 13:15 – 14:30 Lunch